UCB (BATS-CHIXE:UCBB) - Cotización, noticias y análisis

Resumen de acción UCBB

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo.

Acerca de la empresa

UCBB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 64.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 28.68%

Análisis de riesgos

Acciones altamente ilíquidas

Competidores de UCB SA

GSK

LSE:GSK

UK£65.0b

Hikma Pharmaceuticals

LSE:HIK

UK£3.9b

AstraZeneca

LSE:AZN

UK£168.4b

HUTCHMED (China)

AIM:HCM

UK£2.3b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€118.45
52 Week High	€118.73
52 Week Low	€65.58
Beta	0.40
1 Month Change	9.78%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	49.24%
5 Year Change	68.21%
Change since IPO	225.28%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	UCBB	GB Pharmaceuticals	Mercado GB
7D	1.6%	0.2%	-1.4%
1Y	n/a	-5.3%	-2.4%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de UCBB en comparación con el sector UK Pharmaceuticals .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de UCBB frente al mercado UK.

Volatilidad de los precios

Is UCBB's price volatile compared to industry and market?
UCBB volatility
UCBB Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	8.7%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: El precio de las acciones de UCBB ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de UCBB en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1925	8,767	Jean-Christophe Tellier	www.ucb.com

UCB SA, empresa biofarmacéutica, desarrolla productos y soluciones para personas con enfermedades neurológicas e inmunológicas en todo el mundo. Los principales productos de la empresa incluyen Cimzia para enfermedades inflamatorias mediadas por TNF, así como espondilitis anquilosante, espondiloartritis axial, enfermedad de Crohn, espondiloartritis axial no radiográfica, psoriasis en placas, artritis psoriásica y artritis reumatoide; Vimpat, Keppra y Briviact para la epilepsia; Neupro para la enfermedad de Parkinson y el síndrome de las piernas inquietas; Nayzilam, un tratamiento de rescate en aerosol nasal para las crisis de epilepsia; y Zyrtec y Xyzal para las alergias. También ofrece Evenity para el tratamiento de la osteoporosis en mujeres posmenopáusicas; Bimzelx para tratar la psoriasis en placas, la artritis psoriásica y la espondiloartritis axial; y Fintepla para tratar el síndrome de Dravet.

Resumen de fundamentos de UCB SA

¿Cómo se comparan los beneficios e ingresos de UCB con su capitalización de mercado?
Estadísticas fundamentales de UCBB
Capitalización bursátil	€22.75b
Beneficios(TTM)	€343.00m
Ingresos (TTM)	€5.18b

66.3x

Ratio precio-beneficio (PE)

4.4x

Ratio precio-ventas (PS)

¿Está UCBB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de UCBB
Ingresos	€5.18b
Coste de los ingresos	€1.71b
Beneficio bruto	€3.48b
Otros gastos	€3.13b
Beneficios	€343.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	1.81
Margen bruto	67.06%
Margen de beneficio neto	6.62%
Ratio deuda/patrimonio	32.1%

¿Cómo se ha desempeñado UCBB a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.1%

Rentabilidad actual por dividendo

75%

Ratio de pagos

Resumen de acción UCBB

Recompensas

Análisis de riesgos

Competidores de UCB SA

LSE:GSK

UK£65.0b

LSE:HIK

UK£3.9b

LSE:AZN

UK£168.4b

AIM:HCM

UK£2.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

Recent updates

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Revenue beats expectations

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €82.23

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

Rentabilidad de los accionistas